author-photo

Stefan Aebi

University of California, San Diego

100

Papers

4531

Citations

Citation Trend

Filter By

Papers (100) Sort By

JournalConferenceOthers

Abstract OT-26-02: Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive / HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR Trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.

2021 Frontiers in Immunology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P5-12-01: SOLE (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC): Final analysis and sole estrogen substudy (SOLE-EST)

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis

2020 Pharmacological Research
Show All
- Source
- Cite
- Save
Citations (8)
Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial: British Journal of Cancer

2019 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Effets indésirables des immunothérapies oncologiques

2019 Forum Médical Suisse
Show All
- Source
- Cite
- Save
Citations (0)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (172)
Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases

2019 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (6)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号